These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 30326507

  • 1. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A, Montaudie H, Bory P, Belgodere X, Passeron T, Lacour JP, Picard A.
    JAMA Dermatol; 2018 Nov 01; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.
    Eur J Cancer; 2019 Jul 01; 116():148-157. PubMed ID: 31200321
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N, Blakeway E, Mitra A.
    Skinmed; 2019 Jul 01; 17(2):142-143. PubMed ID: 31145074
    [No Abstract] [Full Text] [Related]

  • 8. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY, Khoo C, McCormack CJ, Xu W, Pan Y.
    Australas J Dermatol; 2017 Nov 01; 58(4):322-323. PubMed ID: 28691194
    [No Abstract] [Full Text] [Related]

  • 9. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
    McKenna MC, Molloy K, Crowther S, Feeney J, Gillis A, Connolly M, Kelleher F.
    J Oncol Pract; 2018 Mar 01; 14(3):200-201. PubMed ID: 29300520
    [No Abstract] [Full Text] [Related]

  • 10. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May 01; 26(182):118-119. PubMed ID: 30730667
    [No Abstract] [Full Text] [Related]

  • 11. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.
    Int J Dermatol; 2019 Sep 01; 58(9):1045-1052. PubMed ID: 29152725
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 01; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 14. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M, Legeay AL, Souci S, Streichenberger N, Thomas L, Dalle S.
    Eur J Cancer; 2018 Nov 01; 104():227-230. PubMed ID: 30322679
    [No Abstract] [Full Text] [Related]

  • 15. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
    Parekh V, Gangadhar T, Kreider KL, Elenitsas R, Chu EY.
    JAMA Dermatol; 2017 Jul 01; 153(7):719-721. PubMed ID: 28445579
    [No Abstract] [Full Text] [Related]

  • 16. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C, Reddy BY, Dellavalle RP, Sundararajan S.
    BMJ; 2017 Nov 30; 359():j5174. PubMed ID: 29191943
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.
    Eur J Cancer; 2018 Oct 30; 102():49-51. PubMed ID: 30138772
    [No Abstract] [Full Text] [Related]

  • 18. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
    Montero Pérez O, Sánchez Escudero L, Guzmán Ramos MI, Aviñó Tarazona V.
    Anticancer Drugs; 2022 Jan 01; 33(1):94-99. PubMed ID: 34261922
    [Abstract] [Full Text] [Related]

  • 19. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A, Kneitz H, Schummer P, Herz S, Schrama D, Houben R, Goebeler M, Schilling B, Gesierich A.
    Acta Derm Venereol; 2017 Nov 15; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract] [Full Text] [Related]

  • 20. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N, Uchi H, Furue M.
    J Dermatol; 2017 Oct 15; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.